Comment le bénéfice par action récent de BNTX se compare-t-il aux attentes ?
Comment les revenus de Biontech SE BNTX se sont-ils comportés au dernier trimestre ?
Quelle est l'estimation des revenus pour Biontech SE ?
Quel est le score de qualité des bénéfices pour Biontech SE ?
Quand Biontech SE publie-t-elle ses résultats ?
Quels sont les bénéfices attendus de Biontech SE ?
Biontech SE a-t-elle dépassé les attentes en matière de bénéfices ?
Statistiques clés
Clôture préc.
$106.62
Prix d'ouverture
$106.86
Plage de la journée
$106.86 - $110.28
Plage de 52 semaines
$81.2 - $124.48
Volume
458.5K
Volume moyen
1.2M
BPA (TTM)
-2.36
Rendement en dividend
0.00%
Capitalisation boursière
$26.5B
Qu’est-ce que BNTX ?
BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. The company is headquartered in Mainz, Rheinland-Pfalz and currently employs 6,772 full-time employees. The company went IPO on 2019-10-10. The firm focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The firm is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. The company also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.